GB2613259A - SIRP alpha and SIRP beta 1 antibodies and uses thereof - Google Patents

SIRP alpha and SIRP beta 1 antibodies and uses thereof Download PDF

Info

Publication number
GB2613259A
GB2613259A GB2218419.6A GB202218419A GB2613259A GB 2613259 A GB2613259 A GB 2613259A GB 202218419 A GB202218419 A GB 202218419A GB 2613259 A GB2613259 A GB 2613259A
Authority
GB
United Kingdom
Prior art keywords
seq
antibody
acid sequence
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB2218419.6A
Other languages
English (en)
Other versions
GB202218419D0 (en
Inventor
Panicker Sandip
David Rosenthal Adam
Lingshu Rose Eileen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Electra Therapeutics Inc
Original Assignee
Electra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electra Therapeutics Inc filed Critical Electra Therapeutics Inc
Publication of GB202218419D0 publication Critical patent/GB202218419D0/en
Publication of GB2613259A publication Critical patent/GB2613259A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
GB2218419.6A 2020-05-08 2021-05-10 SIRP alpha and SIRP beta 1 antibodies and uses thereof Withdrawn GB2613259A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063022309P 2020-05-08 2020-05-08
PCT/US2021/031541 WO2021226576A1 (en) 2020-05-08 2021-05-10 Sirp alpha and sirp beta 1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
GB202218419D0 GB202218419D0 (en) 2023-01-18
GB2613259A true GB2613259A (en) 2023-05-31

Family

ID=76197640

Family Applications (2)

Application Number Title Priority Date Filing Date
GB2218419.6A Withdrawn GB2613259A (en) 2020-05-08 2021-05-10 SIRP alpha and SIRP beta 1 antibodies and uses thereof
GB2218421.2A Withdrawn GB2613464A (en) 2020-05-08 2021-05-10 Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB2218421.2A Withdrawn GB2613464A (en) 2020-05-08 2021-05-10 Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof

Country Status (11)

Country Link
US (4) US12503508B2 (https=)
EP (2) EP4146698A1 (https=)
JP (2) JP2023525753A (https=)
KR (2) KR20230017219A (https=)
CN (2) CN115768795A (https=)
AU (2) AU2021267943A1 (https=)
CA (2) CA3177961A1 (https=)
GB (2) GB2613259A (https=)
IL (2) IL298024A (https=)
TW (2) TW202208431A (https=)
WO (2) WO2021226591A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226591A1 (en) 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
CN118591619A (zh) * 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之ｓｉｒｐ抗體
WO2025226691A1 (en) 2024-04-22 2025-10-30 Electra Therapeutics, Inc. Sirp alpha and beta antibodies for treatment of epstein–barr virus infections
CN119192379B (zh) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149938A1 (en) * 2017-02-17 2018-08-23 Ose Immunotherapeutics New uses of anti-sirpg antibodies
WO2018190719A2 (en) * 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2019073080A1 (en) * 2017-10-13 2019-04-18 Ose Immunotherapeutics ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
KR20260030924A (ko) * 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
MA47111A (fr) 2016-12-22 2019-10-30 Univ Wake Forest Health Sciences Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
CN118271443A (zh) * 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
EP3802602A1 (en) * 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
CA3140904A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
US20230340112A1 (en) 2020-02-28 2023-10-26 Apexigen, Inc. Anti-sirpa antibodies and methods of use
WO2021226591A1 (en) * 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
WO2023086906A2 (en) 2021-11-10 2023-05-19 Electra Therapeutics, Inc. Sirp gamma antibodies and uses thereof
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之ｓｉｒｐ抗體
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018149938A1 (en) * 2017-02-17 2018-08-23 Ose Immunotherapeutics New uses of anti-sirpg antibodies
WO2018190719A2 (en) * 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2019073080A1 (en) * 2017-10-13 2019-04-18 Ose Immunotherapeutics ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAN GUO RING ET AL, "Anti-SIRP[alpha] antibody immunotherapy enhances neutrophil and macrophage antitumor activity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20171120), doi:10.1073/pnas.1710877114, ISSN 0027-8424, [X] 1,14,16-31,42-45,54-56,71,81,84-89 * figures 5c,5d * *

Also Published As

Publication number Publication date
US20250197492A1 (en) 2025-06-19
KR20230017793A (ko) 2023-02-06
GB202218421D0 (en) 2023-01-18
JP2023525753A (ja) 2023-06-19
GB2613464A (en) 2023-06-07
AU2021269130A1 (en) 2022-11-24
JP2023525298A (ja) 2023-06-15
EP4146699A1 (en) 2023-03-15
US12503508B2 (en) 2025-12-23
GB202218419D0 (en) 2023-01-18
US12187797B2 (en) 2025-01-07
US20230303685A1 (en) 2023-09-28
US20240239888A1 (en) 2024-07-18
CN115768795A (zh) 2023-03-07
KR20230017219A (ko) 2023-02-03
WO2021226591A1 (en) 2021-11-11
EP4146698A1 (en) 2023-03-15
WO2021226576A1 (en) 2021-11-11
IL297982A (en) 2023-01-01
CA3178038A1 (en) 2021-11-11
TW202208430A (zh) 2022-03-01
CA3177961A1 (en) 2021-11-11
IL298024A (en) 2023-01-01
CN115768796A (zh) 2023-03-07
TW202208431A (zh) 2022-03-01
AU2021267943A1 (en) 2022-11-24
US20230174648A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
GB2613259A (en) SIRP alpha and SIRP beta 1 antibodies and uses thereof
JP2023505318A (ja) ヒト化ｃｌｄｎ１８．２抗体
JP2021501566A5 (https=)
JP7843824B2 (ja) 抗体および使用方法
US12304949B2 (en) Anti-S100A4 humanized antibodies, uses and methods
JP7717687B2 (ja) 腎疾患における抗幹細胞因子抗体及びその使用方法
KR20260008083A (ko) Cd19/cd38 다중특이적 항체
KR20220159989A (ko) C19 c38 이중특이적 항체
KR20250044359A (ko) 항-ccr8 항체 및 사용 방법
CN111295395B (zh) 抗体和使用方法
JPWO2021226576A5 (https=)
US20240209095A1 (en) Anti-human pd-l1 antibodies and their uses
JPWO2021226591A5 (https=)
EP4650368A1 (en) Tetravalent agonists of erythropoietin receptor
WO2024170543A1 (en) Anti-cd44 antibodies and uses thereof
WO2025049343A1 (en) Anti-tslp antibody constructs and uses thereof
JP2025084100A (ja) 抗ｔｎｆｒ２抗体およびその使用の方法
EP4532546A1 (en) Anti-tnfr2 antibodies and methods of use thereof
CN118679183A (zh) 特异性拮抗剂抗sirpg抗体

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)